Alternative splicing in Alzheimer's disease.
Alternative Splicing
Alzheimer’s disease
Antisense oligonucleotides
RNA-Binding proteins
Journal
Aging clinical and experimental research
ISSN: 1720-8319
Titre abrégé: Aging Clin Exp Res
Pays: Germany
ID NLM: 101132995
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
30
06
2019
accepted:
19
09
2019
pubmed:
5
10
2019
medline:
4
5
2021
entrez:
5
10
2019
Statut:
ppublish
Résumé
Alzheimer's disease (AD) is the most frequent neurodegenerative disorder in the elderly, occurring in approximately 20% of people older than 80. The molecular causes of AD are still poorly understood. However, recent studies have shown that Alternative Splicing (AS) is involved in the gene expression reprogramming associated with the functional changes observed in AD patients. In particular, mutations in cis-acting regulatory sequences as well as alterations in the activity and sub-cellular localization of trans-acting splicing factors and components of the spliceosome machinery are associated with splicing abnormalities in AD tissues, which may influence the onset and progression of the disease. In this review, we discuss the current molecular understanding of how alterations in the AS process contribute to AD pathogenesis. Finally, recent therapeutic approaches targeting aberrant AS regulation in AD are also reviewed.
Identifiants
pubmed: 31583531
doi: 10.1007/s40520-019-01360-x
pii: 10.1007/s40520-019-01360-x
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
747-758Subventions
Organisme : Consiglio Nazionale delle Ricerche
ID : Aging: molecular
Organisme : Consiglio Nazionale delle Ricerche
ID : technological innovations for improving the health of the elderly" (Prot. MIUR 2867 25.11.2011)
Organisme : Regione Lombardia
ID : AMANDA
Références
Albert MS, DeKosky ST, Dickson D et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:270–279
pubmed: 21514249
pmcid: 21514249
Ittner LM, Götz J (2011) Amyloid-β and tau—a toxic pas de deux in Alzheimer’s disease. Nat Rev Neurosci 12:65–72
pubmed: 21193853
Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259
pubmed: 1759558
Braak H, Alafuzoff I, Arzberger T et al (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112:389–404
pubmed: 16906426
pmcid: 3906709
Schellenberg GD, Bird TD, Wijsman EM et al (1992) Genetic linkage evidence for a familial Alzheimer’s disease locus on chromosome 14. Science 258:668–671
pubmed: 1411576
Vetrivel KS, Zhang YW, Xu H et al (2006) Pathological and physiological functions of presenilins. Mol Neurodegener 1:4
pubmed: 16930451
pmcid: 1513131
Alonso Vilatela ME, López-López M, Yescas-Gómez P (2012) Genetics of Alzheimer’s disease. Arch Med Res 43:622–631
pubmed: 23142261
Chabot B, Shkreta L (2016) Defective control of pre-messenger RNA splicing in human disease. J Cell Biol 212:13–27
pubmed: 26728853
pmcid: 4700483
Love JE, Hayden EJ, Rohn TT (2015) Alternative splicing in alzheimer’ s disease. J Park Dis Alzheimer’s Dis 2:6
Adusumalli S, Ngian ZK, Lin WQ et al (2019) Increased intron retention is a post-transcriptional signature associated with progressive aging and Alzheimer’s disease. Aging Cell 18:e12928
pubmed: 30868713
pmcid: 6516162
Braggin JE, Bucks SA, Course MM et al (2019) Alternative splicing in a presenilin 2 variant associated with Alzheimer disease. Ann Clin Transl Neurol 6:762–777
pubmed: 31020001
pmcid: 6469258
Han S, Miller J, Byun S et al (2019) Identification of exon skipping events associated with Alzheimer’s disease in the human hippocampus. BMC Med Genomics 12:13
pubmed: 30704480
pmcid: 6357347
Patel H, Hodges AK, Curtis C et al (2019) Transcriptomic analysis of probable asymptomatic and symptomatic alzheimer brains. Brain Behav Immun 80:644–656
pubmed: 31063847
Lee Y, Han S, Kim D et al (2018) Genetic variation affecting exon skipping contributes to brain structural atrophy in Alzheimer’s disease. AMIA Jt Summits Transl Sci Proc 2018:124–131
pmcid: 5961815
Tollervey JR, Wang Z, Hortobágyi T et al (2011) Analysis of alternative splicing associated with aging and neurodegeneration in the human brain. Genome Res 21:1572–1582
pubmed: 21846794
pmcid: 3202275
Treutlein B, Gokce O, Quake SR et al (2014) Cartography of neurexin alternative splicing mapped by single-molecule long-read mRNA sequencing. Proc Natl Acad Sci 111:E1291–E1299
pubmed: 24639501
Liu W, Wang F, Xu Q et al (2017) BCAS2 is involved in alternative mRNA splicing in spermatogonia and the transition to meiosis. Nat Commun 8:14182
pubmed: 28128212
pmcid: 5290162
Hannigan MM, Zagore LL, Licatalosi DD (2017) Ptbp2 controls an alternative splicing network required for cell communication during spermatogenesis. Cell Rep 19:2598–2612
pubmed: 28636946
pmcid: 5543815
Angiolini F, Belloni E, Giordano M et al (2019) A novel L1CAM isoform with angiogenic activity generated by NOVA2-mediated alternative splicing. Elife 8:e44305
pubmed: 30829570
pmcid: 6398979
Giampietro C, Deflorian G, Gallo S et al (2015) The alternative splicing factor Nova2 regulates vascular development and lumen formation. Nat Commun 6:8479
pubmed: 26446569
pmcid: 4633719
Yamamoto ML, Clark TA, Gee SL et al (2009) Alternative pre-mRNA splicing switches modulate gene expression in late erythropoiesis. Blood 113:3363–3370
pubmed: 19196664
pmcid: 2665901
Baralle FE, Giudice J (2017) Alternative splicing as a regulator of development and tissue identity. Nat Rev Mol Cell Biol 18:437–451
pubmed: 28488700
pmcid: 6839889
Martinez NM, Lynch KW (2013) Control of alternative splicing in immune responses: many regulators, many predictions, much still to learn. Immunol Rev 253:216–236
pubmed: 23550649
pmcid: 3621013
Ghigna C, Valacca C, Biamonti G (2008) Alternative splicing and tumor progression. Curr Genomics 9:556–570
pubmed: 19516963
pmcid: 2694562
Darnell RB (2013) RNA protein interaction in neurons. Annu Rev Neurosci 36:243–270
pubmed: 23701460
pmcid: 3889695
Raj B, Blencowe BJ (2015) Alternative splicing in the mammalian nervous system: recent insights into mechanisms and functional roles. Neuron 87:14–27
pubmed: 26139367
Lee S, Cieply B, Yang Y et al (2018) Esrp1-regulated splicing of Arhgef11 isoforms is required for epithelial tight junction integrity. Cell Rep 25:2417–2430.e5
pubmed: 30485810
pmcid: 6371790
Nagasaki H, Arita M, Nishizawa T et al (2005) Species-specific variation of alternative splicing and transcriptional initiation in six eukaryotes. Gene 364:53–62
pubmed: 16219431
Biamonti G, Maita L, Montecucco A (2018) The Krebs cycle connection: reciprocal influence between alternative splicing programs and cell metabolism. Front Oncol 8:408
pubmed: 30319972
pmcid: 6168629
Kornblihtt AR, Schor IE, Alló M et al (2013) Alternative splicing: a pivotal step between eukaryotic transcription and translation. Nat Rev Mol Cell Biol 14:153–165
pubmed: 23385723
Yeo G, Holste D, Kreiman G et al (2004) Variation in alternative splicing across human tissues. Genome Biol 5:R74
pubmed: 15461793
pmcid: 545594
Dillman AA, Hauser DN, Gibbs JR et al (2013) MRNA expression, splicing and editing in the embryonic and adult mouse cerebral cortex. Nat Neurosci 16:499–506
pubmed: 23416452
pmcid: 3609882
Su CH, Dhananjaya D, Tarn WY (2018) Alternative splicing in neurogenesis and brain development. Front Mol Biosci 5:12
pubmed: 29484299
pmcid: 5816070
Licatalosi DD, Darnell RB (2006) Splicing regulation in neurologic disease. Neuron 52:93–101
pubmed: 17015229
Deschênes M, Chabot B (2017) The emerging role of alternative splicing in senescence and aging. Aging Cell 16:918–933
pubmed: 28703423
pmcid: 5595669
Grothe MJ, Sepulcre J, Gonzalez-Escamilla G et al (2018) Molecular properties underlying regional vulnerability to Alzheimer’s disease pathology. Brain 141:2755–2771
pubmed: 30016411
pmcid: 6113636
Twine NA, Janitz K, Wilkins MR et al (2011) Whole transcriptome sequencing reveals gene expression and splicing differences in brain regions affected by Alzheimer’s disease. PLoS ONE 6:e16266
pubmed: 21283692
pmcid: 3025006
Andersen K, Launer LJ, Dewey ME et al (1999) Gender differences in the incidence of AD and vascular dementia: the EURODEM studies. Neurology 53:1992–1997
pubmed: 10599770
Seshadri S, Wolf PA, Beiser A et al (1997) Lifetime risk of dementia and Alzheimer’s disease: the impact of mortality on risk estimates in the Framingham Study. Neurology 49:1498–1504
pubmed: 9409336
Fisher DW, Bennett DA, Dong H (2018) Sexual dimorphism in predisposition to Alzheimer’s disease. Neurobiol Aging 70:308–324
pubmed: 29754747
pmcid: 6368179
Dumitrescu L, Mayeda ER, Sharman K et al (2019) Sex differences in the genetic architecture of Alzheimer’s disease. Curr Genet Med Rep 7:13–21
pubmed: 31360619
pmcid: 6662731
Wang GS, Cooper TA (2007) Splicing in disease: disruption of the splicing code and the decoding machinery. Nat Rev Genet 8:749–761
pubmed: 17726481
De Strooper B, Iwatsubo T, Wolfe MS (2012) Presenilins and γ-secretase: structure, function, and role in Alzheimer disease. Cold Spring Harb Perspect Med 2:a006304
pubmed: 22315713
pmcid: 3253024
De Jonghe C, Cruts M, Rogaeva EA et al (1999) Aberrant splicing in the presenilin-1 intron 4 mutation causes presenile Alzheimer’s disease by increased Aβ42 secretion. Hum Mol Genet 8:1529–1540
pubmed: 10401002
Goode BL, Chau M, Denis PE et al (2002) Structural and functional differences between 3-Repeat and 4-Repeat tau isoforms. J Biol Chem 275:38182–38189
Espinoza M, De Silva R, Dickson DW et al (2008) Differential incorporation of tau isoforms in Alzheimer’s disease. J Alzheimer’s Dis 14:1–16
Buée L, Bussière T, Buée-Scherrer V et al (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33:95–130
pubmed: 10967355
Goedert M, Spillantini MG, Jakes R et al (1989) Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron 3:519–526
Ghetti B, Oblak AL, Boeve BF et al (2015) Invited review: frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging. Neuropathol Appl Neurobiol 41:24–46
pubmed: 25556536
pmcid: 4329416
Donahue CP, Muratore C, Wu JY et al (2006) Stabilization of the tau exon 10 stem loop alters pre-mRNA splicing. J Biol Chem 281:23302–23306
pubmed: 16782711
pmcid: 2072867
Allen M, Kachadoorian M, Quicksall Z et al (2014) Association of MAPT haplotypes with Alzheimer’s disease risk and MAPT brain gene expression levels. Alzheimer’s Res Ther 6:39
Valenca GT, Srivastava GP, Oliveira-Filho J et al (2016) The role of MAPT haplotype H2 and isoform 1N/4R in Parkinsonism of older adults. PLoS ONE 1:e0157452
Hoxha E, Lippiello P, Zurlo F et al (2018) The emerging role of altered cerebellar synaptic processing in Alzheimer’s disease. Front Aging Neurosci 10:396
pubmed: 30542279
pmcid: 6278174
Trabzuni D, Wray S, Vandrovcova J et al (2012) MAPT expression and splicing is differentially regulated by brain region: relation to genotype and implication for tauopathies. Hum Mol Genet 21:4094–4103
pubmed: 22723018
pmcid: 3428157
Trabzuni D, Ramasamy A, Imran S et al (2013) Widespread sex differences in gene expression and splicing in the adult human brain. Nat Commun 4:2771
pubmed: 24264146
pmcid: 3868224
Zou F, Gopalraj RK, Lok J et al (2008) Sex-dependent association of a common low-density lipoprotein receptor polymorphism with RNA splicing efficiency in the brain and Alzheimer’s disease. Hum Mol Genet 17:929–935
pubmed: 18065781
Lambert JC, Ibrahim-Verbaas CA, Harold D et al (2013) Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet 45:1452–1458
pubmed: 24162737
pmcid: 24162737
Raj T, Li YI, Wong G et al (2018) Integrative transcriptome analyses of the aging brain implicate altered splicing in Alzheimer’s disease susceptibility. Nat Genet 50:1584–1592
pubmed: 30297968
pmcid: 6354244
Raj T, Ryan KJ, Replogle JM et al (2014) CD33: increased inclusion of exon 2 implicates the Ig V-set domain in Alzheimer’s disease susceptibility. Hum Mol Genet 23:2729–2736
pubmed: 24381305
Li YI, van de Geijn B, Raj A et al (2016) RNA splicing is a primary link between genetic variation and disease. Science 352:600–604
pubmed: 27126046
pmcid: 5182069
Borreca A, Gironi K, Amadoro G et al (2016) Opposite dysregulation of fragile-X mental retardation protein and heteronuclear ribonucleoprotein C protein associates with enhanced APP translation in Alzheimer disease. Mol Neurobiol 53:3227–3234
pubmed: 26048669
Mueller SG, Weiner MW, Thal LJ et al (2005) The Alzheimer’s disease neuroimaging initiative. Neuroimaging Clin N Am 15:869–877
pubmed: 16443497
pmcid: 2376747
Kong LL, Miao D, Tan L et al (2018) Genome-wide association study identifies RBFOX1 locus influencing brain glucose metabolism. Ann Transl Med 6:436
pubmed: 30596066
pmcid: 6281526
Wamsley B, Jaglin XH, Favuzzi E et al (2018) Rbfox1 mediates cell-type-specific splicing in cortical interneurons. Neuron 100:846–859
pubmed: 30318414
pmcid: 6541232
Alkallas R, Fish L, Goodarzi H et al (2017) Inference of RNA decay rate from transcriptional profiling highlights the regulatory programs of Alzheimer’s disease. Nat Commun 8:909
pubmed: 29030541
pmcid: 5714957
Matsui T, Ingelsson M, Fukumoto H et al (2007) Expression of APP pathway mRNAs and proteins in Alzheimer’s disease. Brain Res 1161:116–123
pubmed: 17586478
Berson A, Barbash S, Shaltiel G et al (2012) Cholinergic-associated loss of hnRNP-A/B in Alzheimer’s disease impairs cortical splicing and cognitive function in mice. EMBO Mol Med 4:730–742
pubmed: 22628224
pmcid: 3494073
Ferreira-Vieira TH, Guimaraes IM, Silva FR et al (2016) Alzheimer’s disease: targeting the cholinergic system. Curr Neuropharmacol 14:101–115
pubmed: 26813123
pmcid: 4787279
Kolisnyk B, Al-Onaizi M, Soreq L et al (2017) Cholinergic surveillance over hippocampal RNA metabolism and Alzheimer’s-like pathology. Cereb Cortex 27:3553–3567
pubmed: 27312991
Lu J, Shu R, Zhu Y (2018) Dysregulation and dislocation of SFPQ disturbed DNA organization in Alzheimer’s disease and frontotemporal dementia. J Alzheimer’s Dis 61:1311–1321
Ke YD, Dramiga J, Schütz U et al (2012) Tau-mediated nuclear depletion and cytoplasmic accumulation of SFPQ in Alzheimer’s and Pick’s disease. PLoS ONE 7:e35678
pubmed: 22558197
pmcid: 3338448
Ray P, Kar A, Fushimi K et al (2011) PSF suppresses tau exon 10 inclusion by interacting with a stem-loop structure downstream of exon 10. J Mol Neurosci 45:453–466
pubmed: 21881826
pmcid: 3893066
Buratti E, Baralle FE (2008) Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease. Front Biosci 13:867–878
pubmed: 17981595
Neumann M, Sampathu DM, Kwong LK et al (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314:130–133
pubmed: 17023659
Amador-Ortiz C, Lin WL, Ahmed Z et al (2007) TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer’s disease. Ann Neurol 61:435–445
pubmed: 17469117
pmcid: 2677204
Wang G, Yang H, Yan S et al (2015) Cytoplasmic mislocalization of RNA splicing factors and aberrant neuronal gene splicing in TDP-43 transgenic pig brain. Mol Neurodegener 10:42
pubmed: 26334913
pmcid: 4557629
Bai B, Hales CM, Chen PC et al (2013) U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer’s disease. Proc Natl Acad Sci 110:16562–16567
pubmed: 24023061
Hales CM, Dammer EB, Diner I et al (2014) Aggregates of small nuclear ribonucleic acids (snRNAs) in Alzheimer’s disease. Brain Pathol 24:344–351
pubmed: 24571648
pmcid: 4096308
Bai B (2018) U1 snRNP alteration and neuronal cell cycle reentry in Alzheimer disease. Front Aging Neurosci 10:75
pubmed: 29628886
pmcid: 5876301
Yang Y, Geldmacher DS, Herrup K (2011) DNA replication precedes neuronal cell death in Alzheimer’s disease. J Neurosci 21:2661–2668
Kroemer G, El-Deiry WS, Golstein P et al (2009) Classification of cell death: recommendations of the nomenclature committee on cell death 2009. Cell Death Differ 12:1463–1467
Heppner FL, Ransohoff RM, Becher B (2015) Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci 16:358–372
pubmed: 25991443
Ule J, Ule A, Spencer J et al (2005) Nova regulates brain-specific splicing to shape the synapse. Nat Genet 37:844–852
pubmed: 16041372
Ruggiu M, Herbst R, Kim N et al (2009) Rescuing Z+ agrin splicing in Nova null mice restores synapse formation and unmasks a physiologic defect in motor neuron firing. Proc Natl Acad Sci 106:3513–3518
pubmed: 19221030
Iruela-Arispe ML, Davis GE (2009) Cellular and molecular mechanisms of vascular lumen formation. Dev Cell 16:222–231
pubmed: 19217424
Solecki DJ, Govek EE, Tomoda T et al (2006) Neuronal polarity in CNS development. Genes Dev 20:2639–2647
pubmed: 17015428
Segura I, De Smet F, Hohensinner PJ et al (2009) The neurovascular link in health and disease: an update. Trends Mol Med 15:439–451
pubmed: 19801203
Quaegebeur A, Lange C, Carmeliet P (2011) The neurovascular link in health and disease: molecular mechanisms and therapeutic implications. Neuron 71:406–424
pubmed: 21835339
Chang JL, Hinrich AJ, Roman B et al (2018) Targeting amyloid-β precursor protein, APP, splicing with antisense oligonucleotides reduces toxic amyloid-β production. Mol Ther 26:1539–1551
pubmed: 29628304
pmcid: 5986716
Hinrich AJ, Jodelka FM, Chang JL et al (2016) Therapeutic correction of ApoER2 splicing in Alzheimer’s disease mice using antisense oligonucleotides. EMBO Mol Med 8:328–345
pubmed: 26902204
pmcid: 4818756
Wasser CR, Herz J (2016) Splicing therapeutics for Alzheimer’s disease. EMBO Mol Med 8:308–310
pubmed: 26902203
pmcid: 4818748
Schoch KM, DeVos SL, Miller RL et al (2016) Increased 4R-tau induces pathological changes in a human-tau mouse model. Neuron 90:941–947
pubmed: 5040069
pmcid: 5040069
Peacey E, Rodriguez L, Liu Y et al (2012) Targeting a pre-mRNA structure with bipartite antisense molecules modulates tau alternative splicing. Nucleic Acids Res 40:9836–9849
pubmed: 22844088
pmcid: 3479178
Rodriguez-Martin T, Garcia-Blanco MA, Mansfield SG et al (2005) Reprogramming of tau alternative splicing by spliceosome-mediated RNA trans-splicing: implications for tauopathies. Proc Natl Acad Sci 102:15659–15664
pubmed: 16230627
Avale ME, Rodríguez-Martín T, Gallo JM (2013) Trans-splicing correction of tau isoform imbalance in a mouse model of tau mis-splicing. Hum Mol Genet 22:2603–2611
pubmed: 23459933
pmcid: 3674800
Espíndola SL, Damianich A, Alvarez RJ et al (2018) Modulation of tau isoforms imbalance precludes tau pathology and cognitive decline in a mouse model of tauopathy. Cell Rep 23:709–715
pubmed: 29669277
Tanaka H, Kondo K, Chen X et al (2018) The intellectual disability gene PQBP1 rescues Alzheimer’s disease pathology. Mol Psychiatry 23:2090–2110
pubmed: 30283027
pmcid: 6250680
György B, Lööv C, Zaborowski MP et al (2018) CRISPR/Cas9 mediated disruption of the Swedish APP allele as a therapeutic approach for early-onset Alzheimer’s disease. Mol Ther Nucl Acids 11:429–440
Konermann S, Lotfy P, Brideau NJ et al (2018) Transcriptome engineering with RNA-targeting type VI-D CRISPR effectors. Cell 173:665–676
pubmed: 29551272
pmcid: 5910255
Radde R, Duma C, Goedert M et al (2008) The value of incomplete mouse models of Alzheimer’s disease. Eur J Nucl Med Mol Imaging 35:S70–S74
pubmed: 18270700
Blencowe BJ (2006) Alternative splicing: new insights from global analyses. Cell 126:37–47
pubmed: 16839875